Use of Argatroban for anticoagulation during cardiopulmonary bypass in a patient with heparin allergy
Open Access
- 1 November 2008
- journal article
- case report
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 34 (5) , 1113-1114
Abstract
The use of Argatroban for treatment of heparin-induced thrombocytopenia (HIT) and for percutaneous coronary intervention in patients with HIT is well described and FDA approved. The use of Argatroban for cardiopulmonary bypass remains off label and the subject of a few case reports. We report the case of a patient with a heparin allergy requiring cardiopulmonary bypass (CPB) for mitral valve replacement. Argatroban was successfully used as anticoagulation for CPB.Keywords
This publication has 3 references indexed in Scilit:
- Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patientThe Annals of Thoracic Surgery, 2003
- Argatroban as an alternative anticoagulant for patients with heparin allergy during coronary bypass surgeryHeart and Vessels, 2003
- The use of argatroban as an anticoagulant for cardiopulmonary bypass in cardiac operationsThe Journal of Thoracic and Cardiovascular Surgery, 2001